Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celcuity Inc.    CELC

CELCUITY INC.

(CELC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celcuity in Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib

04/08/2021 | 02:45pm EDT

By Stephen Nakrosis

Biotechnology company Celcuity Inc. on Thursday said it entered a global licensing agreement with Pfizer Inc., receiving a worldwide license to develop and commercialize that company's gedatolisib.

Gedatolisib is in clinical development for the treatment of patients with certain types of breast cancer.

Under the terms of the deal, Celcuity said, it paid an upfront license fee of $5 million of cash and $5 million of its common stock. Pfizer is also eligible to receive up to $330 million of milestone payments and tiered royalties on potential sales, Celcuity said.

Gedatolisib is currently being evaluated in combination with palbociclib and either letrozole or fulvestrant in a Phase 1b clinical trial in patients with ER+/HER2-negative advanced or metastatic breast cancer, Celcuity said.

"Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted," Celcuity said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

04-08-21 1645ET

Stocks mentioned in the article
ChangeLast1st jan.
CELCUITY INC. 0.87% 26.55 Delayed Quote.189.85%
PFIZER INC. 1.16% 37.6 Delayed Quote.0.98%
All news about CELCUITY INC.
04/12CELCUITY  : Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI..
PU
04/12CELCUITY  : HC Wainwright Adjusts Celcuity's Price Target to $30 From $19, Maint..
MT
04/09AFTER HOURS WATCH LIST SCORECARD : Celc, fubo, prvb
MT
04/09SECTOR UPDATE : Health Care Stocks Continue to Gain Strength Ahead of Closing Be..
MT
04/09UPDATE : Celcuity's Breast Cancer Drug Trial Shows Encouraging Results -- Shares..
MT
04/09SECTOR UPDATE : Health Care Stocks Maintaining Small Friday Advance
MT
04/09MIDDAY REPORT : Wall Street Firmer Midday Amid Producer Prices Spike
MT
04/09Wall Street Treads Water Pre-Bell, US PPI Up 1% in March
MT
04/09SECTOR UPDATE : Health Care Stocks Mostly Flat Ahead of Friday's Market Open
MT
04/08MT NEWSWIRES AFTER HOURS WATCH LIST : Celc, fubo, prvb
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -12,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -25,9x
Yield 2021 -
Capitalization 326 M 326 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 30
Free-Float 41,0%
Chart CELCUITY INC.
Duration : Period :
Celcuity Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELCUITY INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 30,00 $
Last Close Price 26,55 $
Spread / Highest target 13,0%
Spread / Average Target 13,0%
Spread / Lowest Target 13,0%
EPS Revisions
Managers and Directors
NameTitle
Brian F. Sullivan Chairman & Chief Executive Officer
Vicky Hahne Chief Financial Officer
Lance G. Laing Secretary, Director & Chief Science Officer
Arthur P. DeCillis Chief Medical Officer
John Randy MacDonald Senior Vice President-R&D
Sector and Competitors
1st jan.Capitalization (M$)
CELCUITY INC.189.85%326
EXACT SCIENCES CORPORATION-4.04%22 070
GUARDANT HEALTH, INC.23.53%15 988
BGI GENOMICS CO., LTD.-0.71%8 024
INVITAE CORPORATION-6.58%7 681
ADAPTIVE BIOTECHNOLOGIES CORPORATION-27.23%5 991